{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "regularMarketChangePercent": -1.4851471, "regularMarketPrice": 1.99, "exchange": "FRA", "shortName": "VACCITECH (SP.ADR)/1", "longName": "Vaccitech plc", "messageBoardId": "finmb_366057508", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketTime": 1683871252, "earningsTimestamp": 1679692500, "earningsTimestampStart": 1679692500, "earningsTimestampEnd": 1679692500, "trailingAnnualDividendRate": 0.0, "trailingPE": 15.307693, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 0.13, "epsForward": -0.95, "epsCurrentYear": -2.01, "priceEpsCurrentYear": -0.9900498, "sharesOutstanding": 38348700, "bookValue": 6.446, "fiftyDayAverage": 2.2856, "fiftyDayAverageChange": -0.29559994, "fiftyDayAverageChangePercent": -0.12933144, "twoHundredDayAverage": 2.762, "twoHundredDayAverageChange": -0.7720001, "twoHundredDayAverageChangePercent": -0.2795076, "marketCap": 78060936, "forwardPE": -2.0947368, "priceToBook": 0.3087186, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.6 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1620712800000, "priceHint": 4, "regularMarketChange": -0.029999971, "regularMarketDayHigh": 1.99, "regularMarketDayRange": "1.99 - 1.99", "regularMarketDayLow": 1.99, "regularMarketVolume": 100, "regularMarketPreviousClose": 2.02, "bid": 2.12, "ask": 2.2, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 1.99, "averageDailyVolume3Month": 1, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.110000014, "fiftyTwoWeekLowChangePercent": 0.058510646, "fiftyTwoWeekRange": "1.88 - 5.75", "fiftyTwoWeekHighChange": -3.76, "fiftyTwoWeekHighChangePercent": -0.653913, "fiftyTwoWeekLow": 1.88, "fiftyTwoWeekHigh": 5.75, "symbol": "2AB.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Zeus Building", "address2": "Unit 6-10 The Harwell Science and Innovation Campus Rutherford Avenue", "city": "Harwell", "zip": "OX11 0DF", "country": "United Kingdom", "phone": "44 1865 818 808", "website": "https://www.vaccitech.co.uk", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.", "fullTimeEmployees": 33, "companyOfficers": [{"maxAge": 1, "name": "Mr. William J. Enright MBA", "age": 59, "title": "CEO & Director", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 916619, "fmt": "916.62k", "longFmt": "916,619"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Margaret  Marshall M.D.", "age": 65, "title": "Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2022, "totalPay": {"raw": 662041, "fmt": "662.04k", "longFmt": "662,041"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Sarah  Gilbert", "title": "Co-Founder", "fiscalYear": 2020, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Adrian  Hill Ph.D.", "title": "Co-Founder & Scientific Advisor", "fiscalYear": 2020, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Gemma  Brown", "age": 32, "title": "CFO & Company Sec.", "yearBorn": 1990, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Chris  Ellis", "age": 62, "title": "Chief Operating Officer", "yearBorn": 1960, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Nadege  Pelletier Ph.D.", "age": 44, "title": "Chief Scientific Officer", "yearBorn": 1978, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Graham  Griffiths", "age": 43, "title": "Chief Bus. Officer", "yearBorn": 1979, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Elizabeth  Eagling-Vose M.B.A.", "title": "Head of Clinical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Bernie  McDonald", "title": "Head of IP", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}